CORPORATE THREAT TO ACADEMIC MEDICINE

CORPORATE THREAT TO ACADEMIC MEDICINE

To restore balance, academic medical centers should refocus on education, research, and public service; protect trainees from purely profit-driven pressures; and promote physician-leaders who remain directly engaged in patient care and teaching.

More than a century after the Flexner Report warned about commercialization in medicine, business priorities again threaten to overshadow the core mission of academic medicine: patient care, education, and scientific discovery.

SHARED CLINICAL DECISION-MAKING: When Medical Uncertainty Shifts the Burden of Complex Health Decisions onto Patients

SHARED CLINICAL DECISION-MAKING: When Medical Uncertainty Shifts the Burden of Complex Health Decisions onto Patients

In principle, shared clinical decision-making aims to make care more individualized and collaborative. In practice, however, it can place complex judgments about uncertain evidence into the hands of patients who may have limited time, information, or technical expertise to fully evaluate the choices.

CORPORATE TAKEOVERS ARE CHANGING U.S. HEALTHCARE

CORPORATE TAKEOVERS ARE CHANGING U.S. HEALTHCARE

Big investors are buying hospitals, nursing homes, and doctor’s practices. This can bring money and technology—but often puts profits over patients.

Costs up, quality down: Private equity nursing homes have worse staffing and outcomes. Hospital mergers drive prices up.
Doctors under pressure: Loopholes let corporations control practices behind the scenes.

Solutions: Transparency on ownership, quality standards, smarter Medicare/Medicaid rules, and stronger oversight.

BIG PHARMA PARTNERING WITH TELEHEALTH — HELPING PATIENTS or ENCOURAGING BAD PRESCRIBING ?

BIG PHARMA PARTNERING WITH TELEHEALTH — HELPING PATIENTS or ENCOURAGING BAD PRESCRIBING ?

Current rules from the FDA apply to drug companies’ ads, requiring them to show risks. But telehealth companies aren’t held to the same standards — even when they promote the same drugs. That could mislead patients.
Are doctors favoring drugs from partner companies?
Are patients being properly evaluated?
What exactly are the companies paying each other for?
Is the Anti-Kickback Statute (AKS) being violated?